AI주식인사이트AI Stock Insight
B

환인제약

016580KOSPI

62.1 / 100

Reference Date: 2026-09-09

Financial Score25.0 / 40
News Sentiment17.1 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hwanin Pharmaceutical primarily engages in the manufacturing and sales of pharmaceuticals, with psychiatric and neurological drugs accounting for over 80% of total revenue. According to the 2024 IMS DATA, the company holds the top position in the domestic psychotropic drug market. Its affiliated subsidiaries, Ambrobi&F and Asyu, focus on pharmaceutical R&D and comprehensive distribution, respectively.

Number of Employees

671people

Average Salary

75.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
12.11Industry Average 15.005.0Point

In line with industry avg

PBR
0.46Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE
3.41Industry Average 8.001.0Point

Well below industry avg

Debt Ratio
0.33Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲5.5% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼34.1% (2-year basis)

ROE Trend
2.0 / 4

Avg ROE 6.1% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 2Neutral 1Negative 0Average Sentiment Score 68.3

Detailed Momentum

52-week position5.0Point

52w mid range (42%)

Current 10,380Won52-week high 11,93052-week low 9,230
1-month return3.0Point

1m -0.19% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral반기보고서 (2026.06)2026-08-13